# DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

> **NCT06276283** · PHASE2 · RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** DZD9008 plus Bevacizumab

## Key facts

- **NCT ID:** NCT06276283
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-02-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06276283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06276283, "DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06276283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*